LGND
LIGAND PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$317.33
−0.45%Year over year
Reported trailing growth
- Revenue
- +54.9%
- EBITDA
- +696.5%
- EBIT
- +394.5%
- EPS
- +350.9%
- Free cash flow
- +229.2%
- Operating cash flow
- +138.1%
Forward estimates
Based on analyst estimates
- Revenue
- +20.4%
- EBITDA
- +26.8%
- EPS
- +10.5%
Three-year CAGR
- Revenue
- +11.0%
- EBITDA
- +33.4%
- EBIT
- +149.6%
- Net income
- +54.5%
- EPS
- +46.0%
- Free cash flow
- -25.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026